Royalty Aggregators like Royalty Pharma, Ligand, and XOMA are gaining popularity in the biotech industry. These companies buy up royalty rights to pharmaceutical products, providing upfront cash to ...
Ligand’s strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results